Atezolizumab and Bevacizumab: atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL; bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Tecentriq® and Avastin®

Page last updated: 26 July 2019

• Public Summary Document (PSD) March 2019 PBAC Meeting - (PDF 706KB)
• Public Summary Document (PSD) March 2019 PBAC Meeting - (Word 181KB)